NZ308516A - Transdermal therapeutic system (tts) for administering testosterone - Google Patents

Transdermal therapeutic system (tts) for administering testosterone

Info

Publication number
NZ308516A
NZ308516A NZ308516A NZ30851696A NZ308516A NZ 308516 A NZ308516 A NZ 308516A NZ 308516 A NZ308516 A NZ 308516A NZ 30851696 A NZ30851696 A NZ 30851696A NZ 308516 A NZ308516 A NZ 308516A
Authority
NZ
New Zealand
Prior art keywords
tts
therapeutic system
transdermal therapeutic
administering testosterone
testosterone
Prior art date
Application number
NZ308516A
Inventor
Wilfried Fischer
Daniel Bracher
Original Assignee
Hexal Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexal Ag filed Critical Hexal Ag
Publication of NZ308516A publication Critical patent/NZ308516A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

The invention concerns a transdermal therapeutic system for administering testosterone or a testosterone derivative as the active substance.
NZ308516A 1995-05-10 1996-05-10 Transdermal therapeutic system (tts) for administering testosterone NZ308516A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19517145A DE19517145C2 (en) 1995-05-10 1995-05-10 Transdermal therapeutic system (TTS) for administration of testosterone
PCT/EP1996/002013 WO1996035427A1 (en) 1995-05-10 1996-05-10 Transdermal therapeutic system for administering testosterone

Publications (1)

Publication Number Publication Date
NZ308516A true NZ308516A (en) 1999-05-28

Family

ID=7761562

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ308516A NZ308516A (en) 1995-05-10 1996-05-10 Transdermal therapeutic system (tts) for administering testosterone

Country Status (17)

Country Link
EP (1) EP0825865B1 (en)
JP (1) JPH11504643A (en)
CN (1) CN1183723A (en)
AT (1) ATE208200T1 (en)
AU (1) AU702710B2 (en)
BR (1) BR9608255A (en)
CA (1) CA2220358A1 (en)
CZ (1) CZ287678B6 (en)
DE (2) DE19517145C2 (en)
DK (1) DK0825865T3 (en)
HU (1) HUP9801130A3 (en)
NO (1) NO975140L (en)
NZ (1) NZ308516A (en)
PL (1) PL323145A1 (en)
SK (1) SK149797A3 (en)
WO (1) WO1996035427A1 (en)
ZA (1) ZA963743B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1429697A (en) * 1995-12-29 1997-07-28 Cygnus, Inc. Systems and methods for the transdermal administration of androgenic agents
DE69716737T2 (en) * 1996-07-03 2003-03-20 Alza Corp., Palo Alto DEVICES FOR DRUG DELIVERY AND MANUFACTURING METHOD
US6007837A (en) * 1996-07-03 1999-12-28 Alza Corporation Drug delivery devices and process of manufacture
DE19646050A1 (en) * 1996-11-08 1998-05-14 Labtec Gmbh Transdermal therapeutic system e.g. containing testosterone, melatonin
US6174545B1 (en) 1997-07-01 2001-01-16 Alza Corporation Drug delivery devices and process of manufacture
ES2226394T3 (en) * 1998-05-22 2005-03-16 Novosis Ag TRANSDERMAL SYSTEMS CONTAINING ACTIVE SUBSTANCE THAT IS RELEASED CONTROLLED IN TIME.
FR2793689B1 (en) * 1999-05-19 2001-08-24 Pf Medicament TRANSDERMAL DEVICE FOR THE ADMINISTRATION OF TESTOSTERONE OR A DERIVATIVE THEREOF
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US8173155B2 (en) 2004-06-01 2012-05-08 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch
PT1937276E (en) 2005-10-12 2013-02-21 Besins Healthcare Luxembourg Improved testosterone gel and method of use
FR2895679B1 (en) * 2005-12-29 2012-06-08 Pf Medicament STABILIZATION OF TESTOSTERONE IN TRANSDERMAL DEVICES
CN101480399B (en) * 2008-09-25 2011-10-05 宋博 Application of andrusol in preparing medicament for treating asthenospermia
DE102011012712A1 (en) 2011-03-01 2012-09-06 Frank Lehmann-Horn Use of aldosterone receptor antagonists for the treatment of female sexual dysfunction

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4286592A (en) * 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4725439A (en) * 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4704282A (en) * 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4849224A (en) * 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
GB8804164D0 (en) * 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5152997A (en) * 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
MX9202350A (en) * 1991-05-20 1992-11-01 Alza Corp SKIN PENETRATION INCREMENTING COMPOSITIONS USING GLYCEROL MONOLINOLEATE.
CA2075517C (en) * 1992-04-01 1997-03-11 John Wick Transdermal patch incorporating a polymer film incorporated with an active agent
ATE184473T1 (en) * 1992-06-11 1999-10-15 Theratech Inc USE OF GLYCERINE TO ATTENUATE TRANSDERMAL DRUG ADMINISTRATION
EP0695177B1 (en) * 1993-04-20 1998-02-18 Hexal Ag Active substance-containing plaster
DE4313402A1 (en) * 1993-04-23 1994-10-27 Hexal Pharma Gmbh Transdermal preparation of active compound
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women

Also Published As

Publication number Publication date
EP0825865B1 (en) 2001-11-07
HUP9801130A2 (en) 1998-08-28
CZ287678B6 (en) 2001-01-17
BR9608255A (en) 1999-02-02
ATE208200T1 (en) 2001-11-15
NO975140L (en) 1997-11-10
CA2220358A1 (en) 1996-11-14
NO975140D0 (en) 1997-11-07
HUP9801130A3 (en) 2001-03-28
DE19517145C2 (en) 2000-02-24
EP0825865A1 (en) 1998-03-04
ZA963743B (en) 1996-11-18
AU5805096A (en) 1996-11-29
SK149797A3 (en) 1998-05-06
DE19517145C1 (en) 1996-11-28
DK0825865T3 (en) 2002-02-18
CZ351297A3 (en) 1998-03-18
WO1996035427A1 (en) 1996-11-14
AU702710B2 (en) 1999-03-04
JPH11504643A (en) 1999-04-27
CN1183723A (en) 1998-06-03
PL323145A1 (en) 1998-03-16
DE59608150D1 (en) 2001-12-13

Similar Documents

Publication Publication Date Title
BG102200A (en) Transcorneal system for the release of a medicament
ZA9610729B (en) Transdermal device for the delivery of flurbiprofen.
DK0840621T3 (en)
ZA962536B (en) Pharmaceutical composition for transdermal administration.
UA29476C2 (en) Transdermal therapeutic system, containing estradiol
MX9602683A (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutically active substances.
EP0744942A4 (en) Controlled release hydrogel formulation
MX9605023A (en) Imidazolidine-2,4-dione substituted compounds, as pharmaceutically active substances.
IL114294A0 (en) Sterol derivatives
NZ308516A (en) Transdermal therapeutic system (tts) for administering testosterone
AU6801496A (en) Film for the treatment of soils by fumigation
SI0934065T1 (en) Novel cryptophycin derivatives as anti-neoplastic agents
HUP9903348A3 (en) Transdermal therapeutic system (tts) for administering active substances for the teratment of drug dependency or drug addiction
EP0869786A4 (en) Pharmaceutical compounds
ZA966842B (en) Transdermal administration of vorozole.
CA2331414A1 (en) Transdermal therapeutic system for the administration of candesartan
IL96506A0 (en) Transdermal system for administering pharmaceutical compounds under ph control
ZA963744B (en) Topical aciclovir preparation
ZA966083B (en) Agent for transdermal administration containing esters of 13-ethyl-17ß-hydroxy-11-methylene-18,19-dinor-17Ó-pregn-4-en-20-yn-3-one.
CA2305432A1 (en) Method for preventing the misuse of a transdermal therapeutic system
ES2184121T3 (en) FORMULATION FOR THE TREATMENT AND / OR PROFILAXIS OF DEMENTIA.
GB9615710D0 (en) Pharmaceutical preparations for the treatment of sarcocystosis
MX9606264A (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-i-ole compounds as pharmacologically active substances.
MX9801604A (en) Pharmaceutical compounds.
UA36385A (en) Method for treating generalized periodontitis